Post-marketing Clinical Monitoring of Safety and Performance of Breast Tissue Expander for Breast Reconstruction

Exclusion Criteria13

• breast augmentation without reconstruction in at least one breast;
• neoplasia of any type (except breast neoplasia), not yet treated or under treatment, or requiring surgical removal at the time of implantation;
• pregnancy or breastfeeding at the time of implantation;
• smoking, uncontrolled diabetes, obesity (from grade 2) and ASA III/IV;
• active infection not yet treated or being treated at any site at the time of implantation;
• report or record of adverse reactions or intolerance to silicone prior to implantation;
• immune diseases that affect connective tissue in activity or under treatment (e.g. lupus erythematosus, discoid lupus, scleroderma, etc.) at the time of implantation;
• record or report of use of illicit drugs or medications that increase the risk of immediate post-surgical complications (eg, medications that interfere with coagulation);
• high surgical risk or complications in the immediate post-surgery period, estimated before the implantation;
• evidence or report of tissue characteristics that are clinically inconsistent with a successful implantation (eg tissues with excessive fibrosis or compromised vascularization);
• may not have participated in another clinical study up to 6 months before placement of the expander, unless the researcher deems it to be good for the participant and not impact the study;
• previous treatment with radiotherapy;
• any other condition that, based on the opinion of the researcher or designee, may prevent the provision of informed consent, make study participation unsafe, compromise adherence to the protocol, complicate the interpretation of study outcome data or otherwise interfere with the achievement of the study objectives.